Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

MannKind Corporation (MNKD) News: Study 175 n=353 Update, Hyperglycemia & More

Editor’s Note: Related tickers: MannKind Corporation (NASDAQ:MNKD)

Mannkind Corporation (NASDAQ:MNKD) shares down by 12.40% (NYSEPost)
The share prices of MannKind Corporation (NASDAQ:MNKD) had been traded in the price range of $5.70 and $7.62 per share on Tuesday. The company’s share price had had gradually decreased by 12.40 percentage less than the previous day. The opening price is $7.58 per share and closing price $6.61 per share, which is about to a net change of nearly $0.93 less. The share price of MannKind Corporation (NASDAQ:MNKD) had no effect in the 52 week high value $8.06 and 52 week low value $1.79. MannKind Corporation (NASDAQ:MNKD) is a development-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetics and cancer.

MannKind Corporation (NASDAQ:MNKD)

MannKind Completes Afrezza Studies (Nasdaq)
MannKind Corporation (NASDAQ:MNKD) recently completed a phase III study (Study 175: n=353) on its diabetes candidate Afrezza. MannKind Corporation (NASDAQ:MNKD) completed all follow-up visits for the enrolled patients in the study. The company expects to publish data from the study later this summer. The open-label phase III study evaluated Afrezza inhalation powder in patients suffering from type II diabetes. The study assessed Afrezza using the next-generation inhaler in patients whose disease is insufficiently controlled by metformin. Patients enrolled in the study were randomized to either Afrezza or placebo.

MannKind Corporation (MNKD) Concentrate on Healing Products (SBWire)
MannKind Corporation (NASDAQ:MNKD) set focus on the finding, creating and commercializing of healing products for the sufferers who are being affected by struggling with diabetes issues. MannKind Corporation (NASDAQ:MNKD) is at the level of creating AFREZZA, a nourishment blood insulin treatment which is beneficial for the treatment of 1 or 2 types being affected by diabetes issues generally found in adult sufferers for the control of hyperglycemia. The organization has put $930 thousand of his own money for the growth of the said treatment to bring Afrezza to promote.

Buying High the New Winning Investment Strategy? (FXEmpire)
When I evaluate potential stocks to trade, not only do I examine how well the company has done and delivered, but I also look at the stock’s chart potential and technical analysis. …An excellent example of a stock at a 52-week high that I suggested readers keep on their watch lists recently was MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company that is making some great strides in developing therapeutic products for several diseases, including diabetes, cancer, and inflammatory and autoimmune diseases.

MannKind Still Treading Water, So Why Are Investors Surfing? (DailyFinance)
You could say that MannKind Corporation (NASDAQ:MNKD) is treading water a bit these days — at least from the outside perspective. The company won’t announce results from its phase 3 studies of inhalable insulin Afrezza until August. Don’t expect much news from MannKind Corporation (NASDAQ:MNKD) in the meantime. Meanwhile, investors are surfing one giant wave with MannKind Corporation (NASDAQ:MNKD) stock. Shares have surged more than 200% so far in 2013. Is a wipeout potentially in store, or is this the just the beginning of one epic wave?

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!